Point72 Hong Kong’s BioXcel Therapeutics BTAI Stock Holding History

Point72 Hong Kong’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-22	Closed	-$4K	–	295
2022 Q3	$4K	Sell	22 -213	-91%	-$49.5K	﹤0.01%	1801
2022 Q2	$50K	Buy	+235	New	+$49.4K	﹤0.01%	1371
2021 Q4	–	Sell	-224	Closed	-$109K	–	1925
2021 Q3	$109K	Buy	+224	New	+$98.5K	﹤0.01%	1319
2021 Q2	–	Sell	-33	Closed	-$23K	–	1940
2021 Q1	$23K	Buy	+33	New	+$26.5K	﹤0.01%	1442
2020 Q4	–	Sell	-127	Closed	-$88K	–	1736
2020 Q3	$88K	Buy	+127	New	+$95.4K	0.01%	583
2020 Q1	–	Sell	-96	Closed	-$22K	–	981
2019 Q4	$22K	Buy	96 +51	+113%	+$5.13K	0.01%	862
2019 Q3	$5K	Buy	+45	New	+$7.1K	﹤0.01%	808
2018 Q4	–	Sell	-28	Closed	-$3K	–	907
2018 Q3	$3K	Hold	28	–	–	﹤0.01%	737
2018 Q2	$4K	Sell	28 -359	-93%	-$54.8K	﹤0.01%	721
2018 Q1	$63K	Buy	+387	New	+$64.6K	0.03%	410

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BPA

Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

Point72 Hong Kong's BTAI Position: Q4 2022 in Review

Point72 Hong Kong sold out of BioXcel Therapeutics (BTAI) in Q4 2022, closing a stake of 22 shares — an estimated $4K sold.

Point72 Hong Kong first reported a position in BTAI in Q1 2018 and held it in 10 quarters. The position peaked at $109K in Q3 2021. 83 funds tracked by Wall St. Rank hold BTAI as of Q4 2022.

Point72 Hong Kong reported no remaining BioXcel Therapeutics position as of Q4 2022 after selling out during the quarter.
Point72 Hong Kong sold 22 BioXcel Therapeutics shares in Q4 2022, an estimated $4K.
Point72 Hong Kong first reported a position in BioXcel Therapeutics in Q1 2018 and held it in 10 quarters.
Point72 Hong Kong's BioXcel Therapeutics position peaked at $109K in Q3 2021.
83 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2022.

Based on Point72 Hong Kong's 13F filing for Q4 2022, filed 14 Feb 2023.